English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/217956
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

Title

Spanish Cell Therapy Network (TerCel): 15 years of successful collaborative translational research

AuthorsSánchez-Guijo, Fermín M.; García-Olmo, Damián; Prosper, Felipe; Martínez, Salvador; Zapata, Agustín; Fernández-Avilés, Francisco; Toledo-Aral, Juan José; Torres, Miguel; Fariñas, Isabel; Badimón Maestro, Lina; Labandeira-García, José L.; García-Sancho, Javier ; Moraleda, José María
Issue DateJan-2020
PublisherElsevier
CitationCytotherapy 22(1): 1-5 (2020)
AbstractIn the current article we summarize the 15-year experience of the Spanish Cell Therapy Network (TerCel), a successful collaborative public initiative funded by the Spanish government for the support of nationwide translational research in this important area. Thirty-two research groups organized in three programs devoted to cardiovascular, neurodegenerative and immune-inflammatory diseases, respectively, currently form the network. Each program has three working packages focused on basic science, pre-clinical studies and clinical application. TerCel has contributed during this period to boost the translational research in cell therapy in Spain, setting up a network of Good Manufacturing Practice–certified cell manufacturing facilities– and increasing the number of translational research projects, publications, patents and clinical trials of the participating groups, especially those in collaboration. TerCel pays particular attention to the public-private collaboration, which, for instance, has led to the development of the first allogeneic cell therapy product approved by the European Medicines Agency, Darvadstrocel. The current collaborative work is focused on the development of multicenter phase 2 and 3 trials that could translate these therapies to clinical practice for the benefit of patients.
DescriptionOn behalf of TerCel
Publisher version (URL)https://doi.org/10.1016/j.jcyt.2019.11.001
URIhttp://hdl.handle.net/10261/217956
DOIhttp://dx.doi.org/10.1016/j.jcyt.2019.11.001
ISSN1465-3249
E-ISSN1477-2566
Appears in Collections:(IBGM) Artículos
(IBIS) Artículos
(IBMCC) Artículos
(IN) Artículos
Files in This Item:
File Description SizeFormat 
spanishtercel.pdf434,44 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.